

# Florent Petitprez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4845746/publications.pdf>

Version: 2024-02-01

47  
papers

9,254  
citations

186209

28  
h-index

302012

39  
g-index

58  
all docs

58  
docs citations

58  
times ranked

11045  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. <i>Immunity</i> , 2022, 55, 527-541.e5.	6.6	215
2	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
3	FC 130: Kinetics of Renal Injury After Rhabdomyolysis: Implication of Innate Immune Cells and Complement Activation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
4	Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. <i>Kidney International</i> , 2022, 102, 904-916.	2.6	12
5	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643065.	1.3	26
6	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
7	DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification. <i>BMC Bioinformatics</i> , 2021, 22, 473.	1.2	5
8	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
9	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020, 12, 86.	3.6	63
10	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44
11	Genetic determinism of spontaneous masculinisation in XX female rainbow trout: new insights using medium throughput genotyping and whole-genome sequencing. <i>Scientific Reports</i> , 2020, 10, 17693.	1.6	13
12	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
13	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
14	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
15	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020, 26, 4381-4389.	3.2	44
16	Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. <i>Bioinformatics</i> , 2019, 35, i436-i445.	1.8	576
17	From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments. <i>Annals of Oncology</i> , 2019, 30, v811-v812.	0.6	0
18	Immune classification of soft tissue sarcoma predicts clinical outcome. <i>Annals of Oncology</i> , 2019, 30, v689.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 698-715.	12.8	217
20	Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. <i>Scientific Reports</i> , 2019, 9, 13471.	1.6	9
21	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019, 7, 1091-1105.	1.6	153
22	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
23	Revisiting immune escape in colorectal cancer in the era of immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 815-818.	2.9	30
24	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. <i>Haematologica</i> , 2019, 104, 2501-2511.	1.7	40
25	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	3.0	81
26	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
27	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	1.8	219
28	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
29	Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. <i>Oncolmmunology</i> , 2019, 8, e1505174.	2.1	37
30	Association of IL-36 $\beta$ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	2.0	59
31	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 192-196.	1.6	81
32	Abstract PR03: Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic. , 2019, , .		0
33	Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2549-2549.	0.8	0
34	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0
35	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018, 51, 97-102.	2.4	29
36	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 981-988.	2.0	89

#	ARTICLE	IF	CITATIONS
37	Intratumoral classical complement pathway promotes tumor growth in renal cancer. <i>Molecular Immunology</i> , 2018, 102, 205.	1.0	0
38	Immune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome. <i>Annals of Oncology</i> , 2018, 29, vi35.	0.6	1
39	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018, 8, 390.	1.3	46
40	Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial. , 2018, , .		3
41	DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11501-11501.	0.8	7
42	Probing instructions for expression regulation in gene nucleotide compositions. <i>PLoS Computational Biology</i> , 2018, 14, e1005921.	1.5	11
43	Abstract 4045: A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy. , 2018, , .		2
44	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	3.2	252
45	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathyâ€‘associated C3 glomerulopathy. <i>Blood</i> , 2017, 129, 1437-1447.	0.6	120
46	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	2.6	93
47	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	3.8	1,980